All In Biotech

Investigational drug · Phase 3

I-DXd

Also called: DS-7300a, MK-2400, Ifinatamab deruxtecan

Not approved by FDA. In 17 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

17

17 still active

All registered trials

51

Any phase or sponsor naming "I-DXd"

First trial start

2019

Nov 3, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "I-DXd", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Esophageal Squamous Cell Carcinoma
  • Extensive-stage Small-cell Lung Cancer
  • Extensive Stage-small Cell Lung Cancer
  • Oesophageal Squamous Cell Carcinoma
  • Small Cell Lung Cancer Extensive Stage
  • Advanced Solid Tumor
  • Malignant Solid Tumor
  • Small-Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "I-DXd" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 26 on PubMed

Also in development for Small Cell Lung Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • ZG006Phase 38 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor

  • ObrixtamigBI 764532Phase 36 trials

    Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology

  • ABBV-706Phase 34 trials

    AbbVie · Small Cell Lung Cancer, Extensive Stage-Small Cell Lung Cancer (ES-SCLC), Extensive Stage-Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.